Understanding breast cancer through protein and molecular analysis
Breast Cancer Proteomics and Molecular Heterogeneity
Cancer Trials Ireland · NCT01840293
This study is trying to learn more about the proteins and genes in breast cancer tumors to see how they change over time and how they might affect treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1780 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Cancer Trials Ireland (network) |
| Locations | 6 sites (Cork and 5 other locations) |
| Trial ID | NCT01840293 on ClinicalTrials.gov |
What this trial studies
This observational study aims to define the proteomic and molecular characteristics of primary and recurrent/metastatic breast tumors, focusing on the expression of specific proteins and genes such as S100, estrogen receptor, progesterone receptor, and HER2. Patients will undergo standard treatment while tissue and blood samples are collected at various time points, including pre- and post-operative stages. The study also seeks to expand knowledge on the molecular pathways involved in breast cancer progression and their response to treatments, as well as to identify potential serum markers related to cancer progression.
Who should consider this trial
Good fit: Ideal candidates include adults diagnosed with primary breast cancer or those with suspected or confirmed recurrent/metastatic breast cancer.
Not a fit: Patients with non-breast cancer conditions or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of breast cancer biology and better-targeted therapies for patients.
How similar studies have performed: Other studies focusing on proteomics and molecular characteristics in breast cancer have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue Or -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection/biopsy and/or treatment of tumour tissue Or -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection/biopsy and/or treatment of their tumour tissue 2. Patients receiving neoadjuvant treatment are also eligible (if applicable) 3. Patients have to be ≥ 18 years of age 4. Patients must be able to give informed consent
Where this trial is running
Cork and 5 other locations
- Cork University Hospital — Cork, Ireland (RECRUITING)
- Beaumont Hospital — Dublin, Ireland (RECRUITING)
- St James's Hospital — Dublin, Ireland (COMPLETED)
- St. Vincent's University Hospital — Dublin, Ireland (RECRUITING)
- University Hospital Limerick — Limerick, Ireland (ACTIVE_NOT_RECRUITING)
- University Hospital Waterford — Waterford, Ireland (RECRUITING)
Study contacts
- Study coordinator: Cancer Trials Ireland
- Email: info@cancertrials.ie
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Primary Breast Cancer, Recurrent/Metastatic Breast Cancer